Covalent Modulators of Immune Regulatory Transcription Factors IRF8 and IRF5

This study identifies and optimizes covalent small-molecule modulators, culminating in the compound TH-B10, which directly degrades the inflammatory transcription factor IRF8 and secondarily suppresses IRF5 activity to shut down pro-inflammatory gene expression.

The Gist

Imagine your body's immune system is like a massive, highly organized security team. Its job is to spot intruders (like viruses) and sound the alarm. Two specific officers in this team, named IRF5 and IRF8, are the "Generals" who decide when to turn on the alarm and start a massive inflammatory response.

Usually, these Generals are helpful. But in autoimmune diseases (like lupus or rheumatoid arthritis), these Generals get stuck in "overdrive." They keep screaming "Intruder!" even when there's no danger, causing the body to attack itself.

The problem for scientists is that these Generals are undruggable. Think of them as "ghosts" or "mud pies." They don't have a solid shape or a specific "lock" (binding pocket) that a medicine key can fit into. Traditional drugs usually work by finding a keyhole and jamming it shut. But with these proteins, there's no keyhole to find.

The New Strategy: The "Glue" and the "Wrecking Ball"

Instead of trying to find a keyhole, the scientists in this paper decided to use a different approach. They treated these proteins like a piece of furniture that needed to be thrown out.

1. The Sticky Hook (Covalent Binding): They created a molecule called EN1033. Imagine this molecule has a tiny, super-sticky hook on one end (an acrylamide group). This hook is designed to snap onto specific "handles" on the Generals. These handles happen to be a specific type of amino acid called Cysteine.
2. The Wrecking Ball (Degradation): Once the hook snaps onto the General, it doesn't just stop them from working; it tags them for immediate destruction. It's like putting a "Take Out" sticker on a piece of furniture, and the body's internal trash crew (the proteasome) comes and hauls it away to the dump.

The Surprise Discovery

The scientists originally set out to find a way to remove IRF5 (General 5). They found a molecule, EN1033, that did the job. But they noticed something weird: IRF8 (General 8) was disappearing even faster and more aggressively than IRF5.

It turned out that EN1033 was actually a better "wrecking ball" for IRF8.

• The Mechanism: EN1033 glued itself to a specific handle on IRF8 (Cysteine 223) and a different handle on IRF5 (Cysteine 28).
• The Chain Reaction: The scientists realized that IRF8 and IRF5 are best friends who work together. When you knock out IRF8, IRF5 gets confused and stops working too. So, by destroying IRF8, they accidentally (but effectively) shut down IRF5 as well.

The Upgrade: From "Good Enough" to "Great"

The first molecule (EN1033) worked, but it was a bit clumsy. It required high doses and wasn't perfectly precise.

The team then went into their chemistry lab to tinker with the design, like a mechanic tuning a race car engine. They tweaked the shape of the molecule to make it fit the "handle" on IRF8 even better.

This led to their new champion molecule: TH-B10.

• TH-B10 is like a sniper compared to the shotgun blast of EN1033.
• It targets IRF8 with much higher precision and speed.
• Because it destroys IRF8 so efficiently, the "downstream" effect shuts down IRF5 automatically.
• The result? The inflammatory alarm is silenced, and the body stops attacking itself, but the molecule is much cleaner and more effective.

Why This Matters

For decades, scientists thought you couldn't make drugs for these "ghost-like" proteins because they lacked a keyhole. This paper proves that you don't need a keyhole if you have a glue gun.

By using "sticky hooks" to tag these proteins for destruction, the scientists have opened a new door for treating autoimmune diseases. They've shown that even the most elusive targets can be taken down if you change the strategy from "locking the door" to "throwing the whole house out."

In a nutshell: They found a way to stick a "destroy me" tag on two overactive immune generals, with a new, improved version of the tag that works faster and more precisely, potentially offering new hope for people suffering from chronic inflammation.

Technical Summary

1. Problem Statement

Transcription factors (TFs) are historically considered "undruggable" due to their lack of classical deep binding pockets, high intrinsic disorder, and shallow protein-protein interaction interfaces. Despite this, specific TFs like IRF5 and IRF8 are critical drivers of innate immune signaling, pro-inflammatory gene expression, and autoimmune diseases.

• IRF5: A potent driver of pro-inflammatory macrophage activation and cytokine production.
• IRF8: Governs the development of monocytes, dendritic cells, and myeloid lineages; dysregulation is linked to myeloid malignancies and inflammation-associated cancers.
• The Gap: While IRF5 has seen some recent (undisclosed) degrader/inhibitor reports, there are currently no reported small-molecule inhibitors or degraders for IRF8. Traditional small-molecule approaches have failed to target these intrinsically disordered proteins effectively.

2. Methodology

The authors employed a multi-faceted approach combining covalent chemoproteomics, activity-based protein profiling (ABPP), and medicinal chemistry:

• Screening: A library of cysteine-reactive covalent ligands was screened in THP1 macrophage leukemia cells overexpressing HiBiT-tagged IRF5 to identify degraders.
• Mechanistic Validation:
  • Degradation Pathway: Used inhibitors of the ubiquitin-proteasome system (TAK243, Bortezomib) and autophagy/lysosome pathways (Bafilomycin) to determine degradation mechanisms.
  • Target Engagement: Utilized Activity-Based Protein Profiling (ABPP) with clickable alkyne probes (TH3-189) and mass spectrometry (MS/MS) to identify covalent binding sites.
  • Thermal Stability: Employed Cellular Thermal Shift Assay (CETSA) to assess protein destabilization.
  • Mutagenesis: Generated cysteine-to-serine mutants (e.g., C28S, C223S) to validate specific covalent binding sites required for degradation.
  • Chemoproteomics: Performed quantitative proteomics (TMT) and isotopic desthiobiotin-ABPP (isoDTB-ABPP) to assess global selectivity and off-target engagement.
• Functional Assays: Luciferase reporter assays for IRF5 transcriptional activity, RNA-seq for transcriptomic profiling, and Western blotting for protein levels.
• Medicinal Chemistry: Structure-Activity Relationship (SAR) studies were conducted on the initial hit to optimize potency and selectivity.

3. Key Contributions

• Discovery of IRF8 Degraders: The first report of direct-acting, covalent small-molecule degraders for IRF8, a previously undruggable target.
• Dual Targeting Mechanism: Identification of a "pathfinder" molecule (EN1033) that degrades both IRF5 and IRF8, revealing a regulatory axis where IRF8 loss drives secondary IRF5 downregulation.
• Optimized Lead (TH-B10): Development of a more potent and selective compound (TH-B10) that primarily targets IRF8 via covalent modification of Cysteine 223 (C223), leading to secondary suppression of IRF5.
• Validation of Covalent Destabilization: Demonstrated that covalent modification of intrinsically disordered cysteines can thermodynamically destabilize TFs, triggering proteasomal degradation without the need for E3 ligase recruitment (monovalent degraders).

4. Key Results

A. Discovery of EN1033

• Hit Identification: Screening identified EN1033, an acrylamide-containing compound, as a degrader of HiBiT-IRF5.
• Mechanism: EN1033 induces proteasome-dependent degradation (rescued by Bortezomib, not Bafilomycin).
• Unexpected Selectivity: While screened for IRF5, proteomic profiling revealed that EN1033 degraded IRF8 more rapidly and robustly than IRF5.
• Binding Sites: MS/MS and mutagenesis confirmed EN1033 covalently binds:
  • IRF5: Primarily at C28 (C28S mutation rescued degradation).
  • IRF8: Primarily at C223 (C223S mutation rescued degradation).
• Functional Impact: EN1033 inhibited IRF5-dependent transcriptional reporters (R848-stimulated) and reduced inflammatory markers (CD83).

B. Mechanistic Crosstalk

• IRF8 Regulates IRF5: The study found that IRF8 knockdown leads to reduced IRF5 levels, suggesting IRF8 is upstream of IRF5 stability or expression in this context.
• Direct vs. Indirect: While EN1033 directly binds and degrades IRF5 (via C28), the rapid loss of IRF5 in cells is partially driven by the primary degradation of IRF8.

C. Optimization to TH-B10

• SAR Campaign: Screening 21 analogs of EN1033 yielded TH-B10.
• Improved Potency: TH-B10 showed significantly improved potency against IRF8 ($DC_{50} \approx 2.2 \, \mu M$) and IRF5 ($DC_{50} \approx 6.4 \, \mu M$) compared to EN1033.
• Selectivity: TH-B10 degrades IRF8 more rapidly than IRF5. In IRF5-knockout cells, TH-B10 still degraded IRF8, confirming IRF8 is the primary direct target.
• Mechanism Confirmation: TH-B10-mediated IRF8 degradation is abolished in C223S mutants, confirming C223 is the critical "warhead" binding site.
• Transcriptomics: RNA-seq confirmed that TH-B10 treatment downregulates genes associated with IRF5/IRF8 pathways (e.g., IL1A, IL1B, IL6, CXCL10, CD83), effectively shutting down pro-inflammatory programs.

D. Selectivity and Safety

• Off-Targets: Chemoproteomic profiling showed EN1033/TH-B10 engage ~60 off-target cysteines, indicating moderate selectivity typical of early-stage covalent probes.
• Cytotoxicity: EN1033 showed no cytotoxicity in THP1 cells up to 100 $\mu M$ and did not induce stress granules.

5. Significance

• Expanding the Druggable Proteome: This work validates the strategy of targeting intrinsically disordered cysteines in transcription factors to induce destabilization and degradation, bypassing the need for deep binding pockets.
• Therapeutic Potential: By targeting IRF8 and IRF8, these molecules offer a novel therapeutic avenue for autoimmune diseases (e.g., lupus, rheumatoid arthritis) and inflammation-associated cancers (e.g., colon cancer, AML).
• Chemical Biology Tool: TH-B10 serves as a high-quality chemical probe to dissect the transcriptional circuitry of innate immunity and the regulatory relationship between IRF5 and IRF8.
• Future Directions: The authors acknowledge the need for further medicinal chemistry to improve selectivity (reduce off-target cysteine engagement) and in vivo validation to confirm therapeutic efficacy in disease models.

In summary, this paper successfully transitions the concept of covalent destabilizing degraders from oncogenic targets (like MYC and $\beta$-catenin) to the immunological space, providing the first small molecules capable of directly degrading the "undruggable" transcription factor IRF8.